Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy.

Seon-Jae AhnJaeseong OhDo-Yong KimHyoshin SonSungeun HwangHye-Rim ShinEun Young KimHan Sang LeeWoo-Jin LeeJangsup MoonSoon-Tae LeeKeun-Hwa JungKyung-Il ParkKi-Young JungSeungHwan LeeKyung-Sang YuKon Chu Sang Kun Lee

Published in: Epilepsia (2022)

Genetic polymorphisms of the CYP2C19 gene affect the serum LCM concentration. Because efficacy and toxicity are apparently related to serum LCM levels, the genetic phenotype of CYP2C19 should be considered when prescribing LCM for patients with epilepsy.

Keyphrases

genome wide
copy number
primary care
emergency department
dna methylation
gene expression
temporal lobe epilepsy
genome wide identification
electronic health record